Decoding the HPV-Positive HNSCC Paradox: Suppression of Oncogenic Drivers and Inflammatory Signalling Creates a Distinct Tumor Microenvironment

Head and neck squamous cell carcinoma (HNSCC) is a significant global health concern. Though tobacco, alcohol, and betel quid have been previously recognized as the main risk factors for a long time, unique cases of human papillomavirus (HPV) infection-mediated cancer are now a very emerging topic of discussion. HPV-mediated tumors show distinct biological and clinical properties. Interestingly, it has been observed that though HPV-positive HNSCC often is the sole cause for advanced-stage cancers, patients still have far better initial survival outcomes than those with HPV-negative disease. To better understand this paradox, we carried out integrated transcriptomic and epigenomic analyses using TCGA and other publicly available datasets. Our results depict that HPV-positive tumors suppress some key oncogenic drivers, such as MMP1, MMP11, PTHLH, and SPRR2G, along with some very important pro-inflammatory cytokines like IL1?, IL1?, and TNF. Whereas, all of these genes have many-fold higher expression in the HPV-negative scenario. This change in gene expression profile weakens pathways involved in invasion, extracellular matrix remodeling, and chronic inflammation, ultimately creating a less aggressive tumor environment in HPV-positive HNSCC. On a mechanistic level, we observed HPV-positive cells modulating havoc in chromatin regulation. Specifically, they lose H3K27ac and replace RELA binding with p63 at various pro-inflammatory cytokine promoters, shifting the transcriptional control toward epithelial survival pathways. This duality—reduced inflammatory signalling along with reinforced epithelial persistence—helps to understand why HPV-positive tumors are associated with a more favorable prognosis. In summary, our study establishes HPV-positive HNSCC as biologically different cancer types shaped by viral regulation of chromatin, transcription factors, and immune signalling, offering altogether a new insight into the unique clinical outcomes.